Bloomberg -- Actis Capital LLP and Sequoia Capital plan to sell a controlling stake in India’s Paras Pharmaceuticals Ltd. for as much as $700 million, according to three people with direct knowledge of the matter.
Bloomberg -- Actis Capital LLP and Sequoia Capital plan to sell a controlling stake in India’s Paras Pharmaceuticals Ltd. for as much as $700 million, according to three people with direct knowledge of the matter.
